Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Clinical trial NCT05715840 · UNKNOWN

Trial details

NCT number: NCT05715840
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Start date: 2023-01-31
Primary completion: 2024-07-31
Enrollment: 368

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.